\
&
Contact us
Published on | 5 years ago
Programmes ICT NMBP HealthINNO4COV-19 OPEN CALL - Boosting Innovation for COVID-19 Diagnostic, Prevention and Surveillance
Are you working for a company active in healthcare, medicine, biotech, biopharma, and/or IT-related topics (e.g. robotics, automation, electronics, nanotech, etc)? Then have a look at this accessible funding scheme (up to 100k€ subsidy).
Submission deadlines in November 2020, March 2021 and May 2021.
INNO4COV-19 at a Glance
Create a “lab-to-fab” platform and collaboration resource to enable companies and reference laboratories to develop and implement innovative technologies to fight COVID-19.
Website: www.inno4cov19.eu
The INNO4COV-19 Project aims to support the full development to market uptake of technologies at TRL6-7 or higher. It Provides funding to third parties to archive the desiderated objectives.
Eligibility criteria
What they offer
Key dates
The applications will be considered in three different rounds.
More information on the website of the call: www.inno4cov19.eu/open-call
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.